# US 2012/0231077 A1 · Coated Tablets, Their Method of Preparation, and Related Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231077 A1
- Document ID: US20120231077A1
- Status: Published application
- Kind: A1
- Application number: 13/283,326
- Filed: 2011-10-27
- Published: 2012-09-13
- Earliest claimed: 2006-02-10
- Assignees: Sportscom Danmark Aps
- Inventors: Peter B. Samuelsen; Leif Knudsen; Kern Lystrup
- Web page: https://patentgrep.com/patent/US20120231077A1

## CPC

- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 9/282: {Organic compounds, e.g. fats}
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. In particular, a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid.

## Claims

### Claim 1

A tablet comprising
a) a tabletted core comprising
a triglyceride granulate comprising triglycerides containing one or more esterified omega-3 fatty acids, and
excipients, and
b) an enteric coating surrounding the tabletted core, said enteric coating comprising a coating material.

### Claim 2 (depends on 1)

The tablet according to claim 1, wherein the tabletted core additionally comprises one or more vitamins and/or one or more minerals

### Claim 3 (depends on 1)

The tablet according to claim 1, wherein the coating is a pH-sensitive, enteric coating.

### Claim 4 (depends on 1)

The tablet according to claim 1, wherein the tablet releases at most 25% of the triglyceride during the first two hours of testing when performing a dissolution release profile in simulated gastric fluid using Ph. Eur. paddle method at 100 rpm.

### Claim 5 (depends on 1)

The tablet according to claim 1, wherein the tablet releases at least 10% of the triglyceride during the first two hours of testing when performing a dissolution release profile in simulated intestinal fluid using Ph. Eur. paddle method at 100 rpm.

### Claim 6 (depends on 1)

The tablet according to claim 1, wherein the coating material comprises a pharmaceutically acceptable acid-resistant polymer.

### Claim 7 (depends on 1)

The tablet according to claim 1, wherein the coating material has a solubility at 25° C. of at most 5 g coating material per 100 g acidic aqueous solution, at most 2 g coating material per 100 g acidic aqueous solution, at most 5 g coating material per 100 g acidic aqueous solution, at most 10 g coating material per 100 g acidic aqueous solution, or at most 15 g coating material per 100 g acidic aqueous solution, said acid aqueous solution consisting of 1 mM HCl dissolved in demineralised water.

### Claim 8 (depends on 1)

The tablet according to claim 1, wherein the coating material has a solubility at 25° C. of at least 0.5 g coating material per 100 g basic aqueous solution, at least 1 g coating material per 100 g basic aqueous solution, at least 5 g coating material per 100 g basic aqueous solution, at least 10 g coating material per 100 g basic aqueous solution, or at least 15 g coating material per 100 g basic aqueous solution, said basic aqueous solution consisting of 1 mM NaOH dissolved in demineralised water.

### Claim 9 (depends on 1)

The tablet according to claim 1, wherein the coating material comprises at least one material selected from the group consisting of shellac, acid-resistant acrylic polymer, acid-resistant methacrylic polymer, modified cellulose, methacrylic acid copolymers, cellulose acetate (and its succinate and phthalate version), styrol maleic acid co-polymers, polymethacrylic acid/acrylic acid copolymer, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, hydroxyethyl ethyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, cellulose acetate tetrahydrophtalate, acrylic resin, timellitate, shellac, and combinations thereof.

### Claim 10 (depends on 1)

The tablet according to claim 1, wherein the coating material comprises one or more coating additives.

### Claim 11 (depends on 1)

The tablet according to claim 1, wherein the smallest thickness of the coating is at least 5 micron, at least 20 micron, at least 50 micron at least 100 micron, at least 200 micron or at least 400 micron.

### Claim 12 (depends on 1)

The tablet according to claim 1, wherein the thickness of the coating is in the range of 1 micron-5 mm, 10 micron to 1 mm, 25 micron-500 micron, 50 micron-250 micron, or 75 microns-150 micron.

### Claim 13 (depends on 1)

The tablet according to claim 1, wherein the triglyceride granulate has an average granule size in the range of 5 micron-2 mm, 10 micron to 1.50 mm, 25 micron-1 mm, 50 micron-500 micron, or 75 microns-250 micron.

### Claim 14 (depends on 1)

The tablet according to claim 1, wherein the triglyceride granulate comprises in the range of 5-80% triglyceride by weight, 10-70% triglyceride by weight, 15-60% triglyceride by weight, 20-50% triglyceride by weight, or 25-45% triglyceride by weight.

### Claim 15 (depends on 1)

The tablet according to claim 1, wherein the triglyceride granulate comprises in the range of 2-75% esterified omega-3 fatty acids by weight, 5-70% esterified omega-3 fatty acids by weight, 10-60% esterified omega-3 fatty acids by weight, 15-45% esterified omega-3 fatty acids by weight, or 20-40% esterified omega-3 fatty acids by weight.

### Claim 16 (depends on 1)

The tablet according to claim 1, wherein the triglyceride granulate comprises one or more granulate additives.

### Claim 17 (depends on 1)

The tablet according to claim 1, wherein the tabletted core comprises in the range of 20-85% triglyceride granulate by weight, 25-75% triglyceride granulate by weight, 30-70% triglyceride granulate by weight, 35-65% triglyceride granulate by weight, or 40-60% triglyceride granulate by weight.

### Claim 18 (depends on 1)

The tablet according to claim 1, wherein the tabletted core comprises in the range of 10-70% triglyceride by weight, 15-65% triglyceride by weight, 20-60% triglyceride by weight, 25-55% triglyceride by weight, or 30-50% triglyceride by weight.

### Claim 19 (depends on 1)

The tablet according to claim 1, wherein the tabletted core comprises one or more excipients.

### Claim 20

The tablet according to any of the preceding claims, wherein the tablet comprises in the range of 0.1-50% esterified omega-3 fatty acids by weight, such as 0.5-25% esterified omega-3 fatty acids by weight, preferably in the range of 1-20% esterified omega-3 fatty acids by weight, and even more preferably in the range of 2-18% esterified omega-3 fatty acids by weight, such as in the range of 5-15% esterified omega-3 fatty acids by weight.

### Claim 21 (depends on 1)

The tablet according to claim 1, wherein the tablet comprises in the range of 1-99% tabletted core by weight, 10-90% tabletted core by weight, 20-80% tabletted core by weight 25-75% tabletted core by weight, 30-70% tabletted core by weight, or 40-60% tabletted core by weight.

### Claim 22 (depends on 1)

The tablet according to claim 1, wherein the tablet comprises in the range of 1-75% coating by weight, 10-65% coating by weight, 15-60% coating by weight 20-55% coating by weight, 25-50% coating by weight, or of 30-45% coating by weight.

### Claim 23 (depends on 1)

The tablet according to claim 1, wherein the tablet has a weight in the range of 100 mg-5 g, 250 mg-2.5 g, 500 mg-2 g, or 750 mg-1.5 g.

### Claim at position 24

24-26. (canceled)
